111 related articles for article (PubMed ID: 37643005)
1. Flavonoids as potential reactivators of structural mutation p53Y220C by computational and cell-based studies.
Malhotra L; Kaur P; Ethayathulla AS
J Biomol Struct Dyn; 2023 Aug; ():1-12. PubMed ID: 37643005
[TBL] [Abstract][Full Text] [Related]
2. Curcumin rescue p53Y220C in BxPC-3 pancreatic adenocarcinomas cell line: Evidence-based on computational, biophysical, and in vivo studies.
Malhotra L; Goyal HKV; Jhuria S; Dev K; Kumar S; Kumar M; Kaur P; Ethayathulla AS
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129807. PubMed ID: 33278547
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer.
Malhotra L; Sharma S; Hariprasad G; Dhingra R; Mishra V; Sharma RS; Kaur P; Ethayathulla AS
Biochim Biophys Acta Mol Cell Res; 2022 Dec; 1869(12):119343. PubMed ID: 36007676
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53
Radhakrishnan N; Dhanjal JK; Sari AN; Ishida Y; Terao K; Kaul SC; Sundar D; Wadhwa R
Discov Oncol; 2021 Dec; 12(1):64. PubMed ID: 35201513
[TBL] [Abstract][Full Text] [Related]
5. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
6. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
7. Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53.
Kabir M; Sun N; Hu X; Martin TC; Yi J; Zhong Y; Xiong Y; Kaniskan HÜ; Gu W; Parsons R; Jin J
J Am Chem Soc; 2023 Jul; 145(27):14932-14944. PubMed ID: 37365684
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
9. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapeutic strategies for targeting mutant p53-Y220C.
Chasov V; Davletshin D; Gilyazova E; Mirgayazova R; Kudriaeva A; Khadiullina R; Yuan Y; Bulatov E
J Biomed Res; 2024 May; 38(3):222-232. PubMed ID: 38738269
[TBL] [Abstract][Full Text] [Related]
11. Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.
Han ISM; Thayer KM
ACS Omega; 2024 May; 9(18):19837-19847. PubMed ID: 38737036
[TBL] [Abstract][Full Text] [Related]
12. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.
Olotu FA; Soliman MES
J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
Balasundaram A; Doss CGP
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.
Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T
J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418
[TBL] [Abstract][Full Text] [Related]
15. Comparative computational and experimental analyses of some natural small molecules to restore transcriptional activation function of p53 in cancer cells harbouring wild type and p53
Shefrin S; Sari AN; Kumar V; Zhang H; Meidinna HN; Kaul SC; Wadhwa R; Sundar D
Curr Res Struct Biol; 2022; 4():320-331. PubMed ID: 36164647
[TBL] [Abstract][Full Text] [Related]
16. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
Calhoun S; Daggett V
Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
[TBL] [Abstract][Full Text] [Related]
17. Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein.
Das T; Mukhopadhyay C
J Biomol Struct Dyn; 2023 May; 41(8):3368-3381. PubMed ID: 35333136
[TBL] [Abstract][Full Text] [Related]
18. 4-Bromo-4'-chloro pyrazoline analog of curcumin augmented anticancer activity against human cervical cancer, HeLa cells:
Chaudhary M; Kumar N; Baldi A; Chandra R; Babu MA; Madan J
J Biomol Struct Dyn; 2020 Mar; 38(5):1335-1353. PubMed ID: 30957694
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
20. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.
Wassman CD; Baronio R; Demir Ö; Wallentine BD; Chen CK; Hall LV; Salehi F; Lin DW; Chung BP; Hatfield GW; Richard Chamberlin A; Luecke H; Lathrop RH; Kaiser P; Amaro RE
Nat Commun; 2013; 4():1407. PubMed ID: 23360998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
